Ben Fidler's articles Biotechnology Scorpion, fresh off Lilly deal, spins out startup Antares Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its former management team to chase “previously inaccessible” drug targets. Written by Ben Fidler June 11, 2025June 11, 2025 Saving Bookmark this article Bookmarked Biotechnology A bespoke CRISPR therapy suggests a blueprint for treating ‘N-of-1’ diseases A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design and test a new CRISPR medicine in just a few months. Written by Ben Fidler May 15, 2025May 15, 2025 Saving Bookmark this article Bookmarked Biotechnology Roche says it’ll move quickly with ‘differentiated’ obesity drugs CEO Thomas Schinecker claimed the company has “many opportunities” to stand out in the competitive field, and can get to market “much faster” than investors expect. Written by Ben Fidler July 26, 2024July 26, 2024 Saving Bookmark this article Bookmarked Biotechnology Duchenne approval exposes FDA rift over Sarepta gene therapy Peter Marks’ decision to override the objections of agency staff and broaden use of Elevidys could have a “lasting impact” on gene therapy as well as the FDA, one analyst wrote. Written by Ben Fidler June 22, 2024June 22, 2024 Saving Bookmark this article Bookmarked
Biotechnology Scorpion, fresh off Lilly deal, spins out startup Antares Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its former management team to chase “previously inaccessible” drug targets. Written by Ben Fidler June 11, 2025June 11, 2025 Saving Bookmark this article Bookmarked
Biotechnology A bespoke CRISPR therapy suggests a blueprint for treating ‘N-of-1’ diseases A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design and test a new CRISPR medicine in just a few months. Written by Ben Fidler May 15, 2025May 15, 2025 Saving Bookmark this article Bookmarked
Biotechnology Roche says it’ll move quickly with ‘differentiated’ obesity drugs CEO Thomas Schinecker claimed the company has “many opportunities” to stand out in the competitive field, and can get to market “much faster” than investors expect. Written by Ben Fidler July 26, 2024July 26, 2024 Saving Bookmark this article Bookmarked
Biotechnology Duchenne approval exposes FDA rift over Sarepta gene therapy Peter Marks’ decision to override the objections of agency staff and broaden use of Elevidys could have a “lasting impact” on gene therapy as well as the FDA, one analyst wrote. Written by Ben Fidler June 22, 2024June 22, 2024 Saving Bookmark this article Bookmarked
